HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy.


4084 Background: It has been recently confirmed that trastuzumab, a monoclonal antibody against HER2, improves the overall survival in HER2 overexpressing gastric cancers. We investigated the prognostic significance of HER2 status in gastric cancers after curative gastrectomy and adjuvant chemotherapy. METHODS HER2 status was evaluated in 679 gastric… (More)